511
Participants
Start Date
December 31, 2010
Primary Completion Date
September 30, 2013
Study Completion Date
October 31, 2014
Abatacept
Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
Methotrexate
Tablets, oral, 2.5 mg, once weekly, 12 months
Abatacept placebo
Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
Methotrexate placebo
Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
Local Institution, Brussels
Local Institution, Kempton Park
Local Institution, Merksem
Local Institution, Heidelberg
Local Institution, Malvern
Local Institution, Durban
Local Institution, Maroochydore
Local Institution, Cairns
Local Institution, Woodville
Local Institution, Victoria Park
Local Institution, Panorama
Local Institution, Kortrijk
Local Institution, Hjørring
Local Institution, Berlin
Local Institution, Berlin
Alan J. Kivitz, Md, Cpi, Duncansville
Johns Hopkins University Division Of Rheumatology, Baltimore
Carolina Arthritis Associates, Wilmington
Piedmont Rheumatology, Pa, Hickory
Mitchell C. Feinman, Md, Orangeburg
Local Institution, Chihuahua City
Local Institution, Hildesheim
Local Institution, Tampere
Sarasota Arthritis Research Center, Sarasota
Local Institution, Montpellier
Rheumatology Associates Of North Alabama, P.C., Huntsville
Local Institution, Chambray-lès-Tours
Arthritis Associates Of Mississippi, Jackson
Metrohealth Medical Center, Cleveland
Isam A. Diab, Md, Middleburg
Local Institution, Guadalajara
Local Institution, Guadalajara
Local Institution, Metepec
Local Institution, Siena
Kurt Oelke, Md, Glendale
Local Institution, Ancona
Local Institution, Monterrey
Physician Research Collaboration, Llc, Lincoln
St. Joseph'S Mercy Clinic, Hot Springs
Local Institution, Paris
Local Institution, Querétaro
Local Institution, San Luis Potosí City
Local Institution, München
Local Institution, München
Local Institution, München
Coeur D'Alene Arthrit Clin, Coeur d'Alene
Local Institution, Poitiers
Local Institution, Torun
Local Institution, Mérida
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Tver'
Clinical Pharmacology Study Group, Worcester
Local Institution, Calgary
Local Institution, Laval
Local Institution, Helsinki
Local Institution, Lublin
Local Institution, Poznan
Local Institution, Warsaw
Local Institution, Warsaw
Local Institution, Wroc#aw
Local Institution, Pretoria
Local Institution, Pretoria
Local Institution, Pretoria
Local Institution, Daegu
Local Institution, Daejeon
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Gothenburg
Local Institution, Linköping
Local Institution, Malmo
Local Institution, Stockholm
Local Institution, Uppsala
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY